BioSpace News Archive

Drug Development

CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

-Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p<0.0001)-

March 6, 2019
·
13 min read
Business

Newcastle Hospitals Improves Patient Recruitment with CLiX Software

Following the successful conclusion of a pilot study, Clinithink’s CLiX software is now being used by the Newcastle upon Tyne Hospitals NHS Foundation Trust - one of the UK’s leading clinical research centres - to improve patient recruitment in their clinical trials.

March 6, 2019
·
3 min read
PROCARTA ANNOUNCES €1.5 MILLION INVESTMENT FOR NEW CLASS OF ANTIBIOTICS TO COMBAT ANTIMICROBIAL RESISTANCE

The new funding will be used to develop a pipeline of an entirely new class of antibiotic precision medicines from Procarta’s proprietary oligonucleotide-based antimicrobial platform.

March 6, 2019
·
2 min read
Biotech Beach

Millennium Health’s Signals Report™ Identifies Regional and Historical Trends Regarding Prescription and Illicit Drug Use in the United States

A Five-Year Retrospective Analysis of Over Five Million Test Results

March 6, 2019
·
2 min read